Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
chronic obstructive pulmonary disease (COPD)
Pharma
GSK posts COPD win for Nucala as rival nears possible approval
GSK said Nucala and inhaled maintenance therapy lowered the annualized rate of moderate or severe exacerbations among COPD patients for up to 2 years.
Fraiser Kansteiner
Sep 6, 2024 9:40am
FDA delays decision on Sanofi and Regeneron's Dupixent for COPD
May 31, 2024 9:30am
GlobalData, ICER weigh in on Verona's COPD drug ensifentrine
May 30, 2024 12:17pm
Dupixent COPD delay possible, Eylea down 2%, Regeneron says
May 2, 2024 12:00pm
Sanofi is going all in on Dupixent's next potential nod in COPD
Apr 25, 2024 12:37pm
GSK sets $35 out-of-pocket price cap for its inhalers in the US
Mar 21, 2024 11:45am
